EWTX — Edgewise Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Edgewise Therapeutics Inc Receives EMA Orphan Drug Designations For Sevasemten
Brief: Edgewise Therapeutics Announces Positive Two-Year Topline Results From The Arch Open Label Trial Of Sevasemten (Edg-5506) In Adults With Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Edgewise Therapeutics Q4 Basic EPS USD -0.47
Edgewise Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Edgewise Therapeutics Pricing Of Underwritten Offering Of 21.8 Mln Shares Of Common Stock At Offering Price Of $11 Per Share
Brief: Edgewise Therapeutics Inc As Of Dec 31, 2023, Co Had About $318.4 Million In Cash, Cash Equivalents & Marketable Securities
Edgewise Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Edgewise Therapeutics Announces Expansion Of Edg-5506 Clinical Program In Duchenne Muscular Dystrophy
Brief: Edgewise Therapeutics Announces Initiation Of Grand Canyon, A Global Pivotal Study Of Edg-5506 In Becker Muscular Dystrophy
Brief: Edgewise Therapeutics Begins Dosing First-In-Human Phase 1 Trial Of EDG-7500
U.S. RESEARCH ROUNDUP-Dollar Tree, Hexcel, Humacyte
Edgewise Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Edgewise Therapeutics Q2 Operating Income USD -25.339 Million
Edgewise Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Edgewise Therapeutics Says On July 10, Got Notice Co No Longer In Compliance With Listing Rule
U.S. RESEARCH ROUNDUP- Carnival, Nike, Paychex
Brief: Edgewise Therapeutics Announces Positive 12-Month Topline Results From Arch Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy
Brief: Edgewise Therapeutics On June 21 Notified Nasdaq Upon Director Resignation, Co Will No Longer Be In Compliance With Nasdaq Listing Rule 5605(C)(2)(A)